Emerging topics in anaemia and cancer

Supportive care and palliative care: a time for unity in diversity

(2012) M. S. Aapro   ANNALS OF ONCOLOGY

Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer

(2012) M Aapro et al.   BRITISH JOURNAL OF CANCER

PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin–cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer—outcome on prognosis

(2011) M. Untch et al.   ANNALS OF ONCOLOGY

PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer—results at the time of surgery

(2011) M. Untch et al.   ANNALS OF ONCOLOGY

Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference

(2010) F. Roila et al.   ANNALS OF ONCOLOGY

Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for use

(2010) D. Schrijvers et al.   ANNALS OF ONCOLOGY

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours

(2010) M.S. Aapro et al.   EUROPEAN JOURNAL OF CANCER